ChemicalBook > CAS DataBase List > JNJ-7706621

JNJ-7706621

Product Name
JNJ-7706621
CAS No.
443797-96-4
Chemical Name
JNJ-7706621
Synonyms
CS-409;JNJ-7706621 ，S1249;JNJ-7706621 USP/EP/BP;JNJ7706621; JNJ 7706621;JNJ-7706621, 10 mM in DMSO;Aurora Kinase/Cdk Inhibitor;JNJ-7706621 JNJ7706621 Aurora Kinase Cdk Inhibitor;Aurora Kinase/Cdk Inhibitor - CAS 443797-96-4 - Calbiochem;4-[[5-Amino-1-(2,6-difluorobenzoyl)-1,2,4-triazol-3-yl]amino]benzenesulfonamide;4-[[5-Amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl]amino]benzenesulfonamide
CBNumber
CB62484646
Molecular Formula
C15H12F2N6O3S
Formula Weight
394.36
MOL File
443797-96-4.mol
More
Less

JNJ-7706621 Property

Melting point:
149-155℃
Boiling point:
676.6±65.0 °C(Predicted)
Density 
1.71
storage temp. 
+2C to +8C
solubility 
Soluble in DMSO at 15mg/ml
form 
White solid
pka
9.80±0.12(Predicted)
color 
White to off-white
Sensitive 
Light Sensitive
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Warning
Hazard statements

H302Harmful if swallowed

H315Causes skin irritation

H319Causes serious eye irritation

H335May cause respiratory irritation

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P304+P340IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

P405Store locked up.

More
Less

N-Bromosuccinimide Price

Sigma-Aldrich
Product number
189406
Product name
Aurora Kinase/Cdk Inhibitor - CAS 443797-96-4 - Calbiochem
Packaging
5mg
Price
$352
Updated
2025/07/31
Cayman Chemical
Product number
18494
Product name
JNJ-7706621
Purity
≥98%
Packaging
1mg
Price
$44
Updated
2024/03/01
Cayman Chemical
Product number
18494
Product name
JNJ-7706621
Purity
≥98%
Packaging
5mg
Price
$193
Updated
2024/03/01
Cayman Chemical
Product number
18494
Product name
JNJ-7706621
Purity
≥98%
Packaging
10mg
Price
$341
Updated
2024/03/01
TRC
Product number
J211310
Product name
JNJ-7706621
Packaging
50mg
Price
$865
Updated
2021/12/16
More
Less

JNJ-7706621 Chemical Properties,Usage,Production

Description

JNJ-7706621 is a dual inhibitor of cyclin-dependent kinases (CDKs) and Aurora kinases. It potently inhibits Cdk1/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E, Cdk3/cyclin E, Cdk4/cyclin D1, Cdk6/cyclin D1, Aurora A, and Aurora B in vitro (IC50s = 9, 4, 3, 58, 253, 175, 11, and 15 nM, respectively). It shows selectivity for these enzymes over a panel of other receptors and kinases, although it exhibits submicromolar inhibition of VEGF and FGF receptors, as well as GSK3β. JNJ-7706621 blocks the growth of a large variety of cancer cell lines (IC50 values range from 112 to 514 nM), with lower potency against normal cells (IC50 values between 3.67 and 5.42 μM). It induces the regression of A375 melanoma human tumor xenografts in mice. JNJ-7706621 is a substrate for the ATP-binding cassette transporter G2, also known as breast cancer resistance protein.

Uses

JNJ-770662 is a broad spectrum inhibitor of cyclin-dependent kinases and aurora kinases including CDK1/Cyclin B, CDK2/Cyclin A, CDK2/Cyclin E, Aurora-A and Aurora-B. JNJ-770662 has been shown to induce growth suppression and mitotic defects, these results suggest that JNJ-7706621 could be useful for cell cycle analysis and therapy of various cancers, including Ewing''s sarcoma.

Definition

ChEBI: 4-[[5-amino-1-[(2,6-difluorophenyl)-oxomethyl]-1,2,4-triazol-3-yl]amino]benzenesulfonamide is a sulfonamide.

Synthesis

172935-91-0

700805-72-7

443797-96-4

The general procedure for the synthesis of 4-[[5-amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl]amino]benzenesulfonamides from 2,6-difluorobenzohydrazide and N-[4-(aminosulfonyl)phenyl]-N'-cyanocarbamoyl phenyl ester (CAS: 700805-72-7) was as follows: a series of experiments were carried out to examine solvent and base effects on the yield of the target product as determined by HPLC. The experiments were performed as follows: N-[4-(aminosulfonyl)phenyl]-N'-cyanocarbamic acid phenyl ester (0.5 g, 1.60 mmol) and 2,6-difluorobenzoyl hydrazine (0.3 g, 1.74 mmol) were dissolved in 15 mL of the solvent of choice, and the base of choice was added with stirring (2.08 mmol, 1.3 eq., see Table 4). The reaction mixture was heated to 80-85 °C and maintained at this temperature for 6 hours. After completion of the reaction, the mixture was cooled to 20-25 °C and sampled for HPLC analysis.The HPLC samples were prepared by diluting aliquots with acetonitrile and water (50/50) to determine the percentage conversion to 4-[[5-amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl]amino]benzenesulphonamide and the results are presented in Table 4. Table 4: Effect of solvent and base on the yield of the target producta,b. Different amounts of isourea exchange product and decomposition were observed in all cases, except for the case where pyridine was used.c. HPLC analysis showed c-3% of the other regional isomer.d. HPLC analysis showed ~1.4% of the other regional isomer.e. The results are presented in Table 4.

in vivo

JNJ-7706621 (100 and 125 mg/kg) is efficacious in a human tumor xenograft model under intermittent dosing regimens[3]. JNJ-7706621 (100 mg/kg, i.p.) exhibits 95% tumor growth inhibition in A375 (human melanoma) tumor xenograft model[1]. JNJ-7706621-loaded micelles inhibit tumor growth, and delay the tumor growth more efficiently than the control JNJ-7706621 suspension[4].

target

CDK1

IC 50

CDK6/cyclinD1: 175 nM (IC50); CDK2/cyclinE: 3 nM (IC50); Cdk4/cyclin D1: 253 nM (IC50); Cdk1/cyclin B: 9 nM (IC50); cdk2/cyclin A: 4 nM (IC50); CDK3/Cyclin E: 58 nM (IC50); Aurora A: 11 nM (IC50); Aurora B: 15 nM (IC50); VEGF-R2: 154 nM (IC50); VEGF-R1: 6400 nM (IC50); VEGF-R3: 735 nM (IC50); FGF-R1: 575 nM (IC50); FGF-R2: 226 nM (IC50); GSK3β: 254 nM (IC50)

References

[1] Patent: WO2005/77922, 2005, A2. Location in patent: Page/Page column 46
[2] Patent: WO2005/77922, 2005, A2. Location in patent: Page/Page column 48-49
[3] Patent: WO2005/77922, 2005, A2. Location in patent: Page/Page column 54-55
[4] Patent: WO2005/77922, 2005, A2. Location in patent: Page/Page column 50-51
[5] Patent: WO2005/77922, 2005, A2. Location in patent: Page/Page column 50-51

JNJ-7706621 Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

JNJ-7706621 Suppliers

China 118 Germany 1 India 2 United Kingdom 1 United States 20 Global 142
Shanghai Boyle Chemical Co., Ltd.
Tel
Fax
86-21-57758967
Email
sales@boylechem.com
Country
China
ProdList
2922
Advantage
55
J & K SCIENTIFIC LTD.
Tel
18210857532; 18210857532
Fax
86-10-82849933
Email
jkinfo@jkchemical.com
Country
China
ProdList
96815
Advantage
76
VDM Biochemicals
Tel
0330-2528181
Fax
0330-2528171
Email
sales@vdmbio.com
Country
United States
ProdList
510
Advantage
64
Nanjing Chemlin Chemical Co., Ltd
Tel
025-83697070
Fax
+86-25-83453306
Email
info@chemlin.com.cn
Country
China
ProdList
15883
Advantage
64
Jinan Trio PharmaTech Co., Ltd.
Tel
0531-88811783
Fax
+86 (531) 55696010 QQ 1762738062
Email
sales@trio-pharmatech.com
Country
China
ProdList
1856
Advantage
62
Xi’an chemsoar Medical Technology Co., ltd
Tel
029-86538357
Fax
029-87871708
Country
China
ProdList
234
Advantage
57
Dalian Meilun Biotech Co., Ltd.
Tel
0411-62910999 13889544652
Email
sales@meilune.com
Country
China
ProdList
4747
Advantage
58
Shanghai civi chemical technology co.,Ltd
Tel
86-21-34053660
Fax
86-21-34053661
Email
sale@labgogo.com
Country
China
ProdList
9865
Advantage
52
NCE Biomedical Co.,Ltd.
Tel
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988
Fax
+86-27-87599188
Country
China
ProdList
1493
Advantage
55
Haoyuan Chemexpress Co., Ltd.
Tel
021-58950125
Fax
(86) 21-58955996
Email
info@chemexpress.com
Country
China
ProdList
7552
Advantage
61

443797-96-4, JNJ-7706621Related Search:

JNJ-10229570 JNJ0966 JNJ-38158471 N-[2-(1H-Indol-3-yl)ethyl]-N'-(4-pyridinyl)-1,4-benzenediamine TRC253 3-(cyclopropylMethyl)-7-(4-phenylpiperidin-1-yl)-8-(trifluoroMethyl)-[1,2,4]triazolo[4,3-a]pyridine JNJ 63533054 JNJ-26481585 N-(4-chloropyridin-3-yl)-4-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)Methyl)piperazine-1-carboxaMide JNJ 31020028 JNJ-632 2-(4-Chlorophenoxy)-2-methyl-N-[5-[(methylsulfonyl)amino]tricyclo[3.3.1.13,7]dec-2-yl]-propanamide ZM 447439 Ribociclib Orantinib (SU6668) BI-D1870 CCT129202 AT9283

  • 4-[[5-Amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl]amino]benzenesulfonamide JNJ7706621
  • 4-[[5-Amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl]amino]benzenesulfonamide
  • Aurora Kinase/Cdk Inhibitor
  • Aurora Kinase/Cdk Inhibitor - CAS 443797-96-4 - Calbiochem
  • CS-409
  • JNJ7706621; JNJ 7706621
  • Benzenesulfonamide, 4-[[5-amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl]amino]-
  • 4-[[5-Amino-1-(2,6-difluorobenzoyl)-1,2,4-triazol-3-yl]amino]benzenesulfonamide
  • JNJ-7706621 USP/EP/BP
  • JNJ-7706621 JNJ7706621 Aurora Kinase Cdk Inhibitor
  • Cyclin dependent kinase,CDK,JNJ-7706621,Apoptosis,JNJ7706621,inhibit,Inhibitor,Aurora Kinase
  • JNJ-7706621, 10 mM in DMSO
  • JNJ-7706621 ，S1249
  • 443797-96-4
  • C15H12F2N6O3S
  • Inhibitor
  • Inhibitors
  • JNJ-7706621